Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:24:08.011Z.
Calculation as of: 2026-10-06T19:24:08.011Z.
Quote observation: 2026-10-06T19:20:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$69.09M
EV/EBITDA Ratio
3.38x
TTM Avg
7.89x
3Y Avg
4.27x
5Y Avg
4.27x
Market Cap
$69.88M
EV/EBITDA Ratio
262.88x
TTM Avg
103.53x
3Y Avg
75.29x
5Y Avg
64.49x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $68.72M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.27M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.09M | 3.38x | 7.89x | 4.27x | 4.27x |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | 262.88x | 103.53x | 75.29x | 64.49x |
| Cingulate Inc. (CING)vs › | $66.27M | 0.23x | 0.03x | 0.03x | 0.03x |
| iBio, Inc. (IBIO)vs › | $66.24M | N/A | N/A | N/A | N/A |
| XBiotech Inc. (XBIT)vs › | $66.01M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.20M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.83M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
